Lei Yang | Oncology | Best Researcher Award

Published on by Best Achievements

Prof. Lei Yang | Oncology | Best Researcher Award

Prof. Lei Yang | Guangzhou Medical University | China

Prof. Lei Yang, Ph.D. supervisor at Guangzhou Medical University, is a distinguished researcher specializing in respiratory disease biomarkers and epidemiology. Recognized as a Guangdong “Special Support Plan” Young Talent, he has led multiple NSFC projects, contributed to national R&D programs, and authored over 69 publications with an H-index of 27. His innovations include patents, software copyrights, and a lung cancer detection kit, significantly advancing early diagnosis and precision medicine. He also actively serves on professional committees, contributing to cancer research and public health.

Profiles

Scopus 
Orcid
Google Scholar 

Early Academic Pursuits

Prof. Lei Yang demonstrated strong academic promise early in his career, pursuing studies in biomedical sciences and respiratory medicine. His scholarly journey led him to specialize in biomarker screening and epidemiology, laying the foundation for impactful research in respiratory diseases. His early academic training not only strengthened his expertise in data analysis and disease mechanisms but also prepared him for future leadership roles in medical research and innovation.

Professional Endeavors

Currently a Professor at Guangzhou Medical University and PhD supervisor, Prof. Yang has made significant professional strides in the field of respiratory disease research. Recognized as a Guangdong “Special Support Plan” Young Talent, he has successfully led five NSFC projects, participated in national key R&D programs, and collaborated on major initiatives such as the Precision Medicine Research Special Project. His professional journey reflects a balance of teaching, mentoring, and high-impact research.

Contributions and Research Focus

Prof. Yang’s research focus lies in the screening of biomarkers for respiratory diseases, with special emphasis on lung cancer early detection and high-risk population identification. His team systematically explored the diagnostic value of plasma exosomal non-coding RNAs, leading to the development of a detection kit for clinical application. Moreover, his genome-wide association studies (GWAS) identified novel genetic susceptibility loci, enriching the understanding of lung cancer pathogenesis and paving the way for precision screening and treatment strategies.

Impact and Influence

The impact of Prof. Yang’s work is evident in both scientific advancement and clinical practice. With over 69 publications, including articles in prestigious journals like the American Journal of Respiratory and Critical Care Medicine, his research has been widely cited, achieving an H-index of 27. His contributions have advanced early diagnostic methods, enhanced understanding of genetic risk factors, and influenced public health strategies for respiratory diseases. His achievements continue to shape the future of oncology and respiratory medicine in China and beyond.

Research Skills

Prof. Yang is proficient in biomarker discovery, molecular epidemiology, genome-wide association studies (GWAS), and large-scale data analysis. His expertise extends to the design and implementation of cohort studies, as seen in his involvement in the South China chronic disease prospective cohort project. Additionally, his ability to integrate laboratory research with clinical application demonstrates strong translational research skills that contribute to real-world healthcare solutions.

Awards and Honors

Prof. Yang has received several prestigious honors, including the Ministry of Education Natural Science Second Prize. His recognition as a Guangdong “Special Support Plan” Young Talent underscores his leadership in medical research. He also holds two patents and three software copyrights, reflecting his innovative contributions to respiratory health diagnostics. These accolades highlight both his scientific excellence and his role as a pioneer in translational medicine.

Legacy and Future Contributions

Prof. Yang’s legacy is being built through his groundbreaking work in lung cancer diagnostics and biomarker innovation. His future contributions are likely to further advance precision medicine, strengthen population-based cohort studies, and drive clinical applications of novel biomarkers. By integrating cutting-edge genomic research with practical medical solutions, Prof. Yang is set to leave a lasting mark on respiratory disease prevention, diagnosis, and treatment, inspiring the next generation of medical researchers and innovators.

Publications Top Notes

Title: A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese
Journal: Nature Genetics 43 (8), 792–796 (2011)
Citations: 432
Authors: Z Hu, C Wu, Y Shi, H Guo, X Zhao, Z Yin, L Yang, J Dai, L Hu, W Tan, Z Li, …

Title: Overexpression of lncRNA IGFBP4–1 reprograms energy metabolism to promote lung cancer progression
Journal: Molecular Cancer 16 (1), 154 (2017)
Citations: 130
Authors: B Yang, L Zhang, Y Cao, S Chen, J Cao, D Wu, J Chen, H Xiong, Z Pan, L Yang, …

Title: A functional polymorphism at microRNA-629-binding site in the 3′-untranslated region of NBS1 gene confers an increased risk of lung cancer in Chinese
Journal: Carcinogenesis 33 (2), 338–347 (2012)
Citations: 107
Authors: L Yang, Y Li, M Cheng, D Huang, J Zheng, B Liu, X Ling, Q Li, X Zhang, …

Title: MicroRNA-152 targets DNA methyltransferase 1 in NiS-transformed cells via a feedback mechanism
Journal: Carcinogenesis 34 (2), 446–453 (2013)
Citations: 91
Authors: W Ji, L Yang, J Yuan, L Yang, M Zhang, D Qi, X Duan, A Xuan, W Zhang, …

Title: Common genetic variation in ETV6 is associated with colorectal cancer susceptibility
Journal: Nature Communications 7 (1), 11478 (2016)
Citations: 89
Authors: M Wang, D Gu, M Du, Z Xu, S Zhang, L Zhu, J Lu, R Zhang, J Xing, X Miao, L Yang, …

Title: Identification of three circular RNA cargoes in serum exosomes as diagnostic biomarkers of non–small-cell lung cancer in the Chinese population
Journal: The Journal of Molecular Diagnostics 22 (8), 1096–1108 (2020)
Citations: 85
Authors: J Xian, W Su, L Liu, B Rao, M Lin, Y Feng, F Qiu, J Chen, Q Zhou, Z Zhao, L Yang, …

Title: Association between chronic obstructive pulmonary disease and lung cancer: a case-control study in Southern Chinese and a meta-analysis
Journal: PLoS One 7 (9), e46144 (2012)
Citations: 81
Authors: H Wang, L Yang, L Zou, D Huang, Y Guo, M Pan, Y Tan, H Zhong, W Ji, …

Title: Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations
Journal: Carcinogenesis 33 (12), 2409–2416 (2012)
Citations: 79
Authors: J Zheng, L Jiang, L Zhang, L Yang, J Deng, Y You, N Li, H Wu, W Li, J Lu, …

Title: A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer
Journal: The American Journal of Human Genetics 91 (2), 384–390 (2012)
Citations: 79
Authors: B Liu, L Yang, B Huang, M Cheng, H Wang, Y Li, D Huang, J Zheng, Q Li, …

Title: NFκB1 and NFκBIA Polymorphisms Are Associated with Increased Risk for Sporadic Colorectal Cancer in a Southern Chinese Population
Journal: PLoS One 6 (6), e21726 (2011)
Citations: 79
Authors: S Song, D Chen, J Lu, J Liao, Y Luo, Z Yang, X Fu, X Fan, Y Wei, L Yang, …

Title: The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in southern and eastern Chinese populations
Journal: Human Mutation 32 (11), 1299–1308 (2011)
Citations: 71
Authors: J Lu, L Yang, H Zhao, B Liu, Y Li, H Wu, Q Li, B Zeng, Y Wang, W Ji, …

Title: A functional copy number variation in the WWOX gene is associated with lung cancer risk in Chinese
Journal: Human Molecular Genetics 22 (9), 1886–1894 (2013)
Citations: 68
Authors: L Yang, B Liu, B Huang, J Deng, H Li, B Yu, F Qiu, M Cheng, H Wang, …

Title: A Sequence Polymorphism in miR-608 Predicts Recurrence after Radiotherapy for Nasopharyngeal Carcinoma
Journal: Cancer Research 73 (16), 5151–5162 (2013)
Citations: 61
Authors: J Zheng, J Deng, M Xiao, L Yang, L Zhang, Y You, M Hu, N Li, H Wu, W Li, …

Title: A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression
Journal: Carcinogenesis 34 (10), 2292–2299 (2013)
Citations: 51
Authors: M Cheng, L Yang, R Yang, X Yang, J Deng, B Yu, D Huang, S Zhang, …

Conclusion

Prof. Lei Yang is a distinguished researcher whose work on respiratory disease biomarkers and lung cancer early detection has made significant scientific and clinical impact. With an impressive record of 69 publications, H-index of 27, multiple patents, and national-level projects, he has demonstrated innovation and leadership in advancing precision medicine. While greater international collaborations and industry partnerships could further enhance his global presence, his strong achievements make him highly suitable for the Research for Best Researcher Award.

Dukagjin Blakaj | Oncology | Best Researcher Award

Published on by Best Achievements

Prof. Dr. Dukagjin Blakaj | Oncology | Best Researcher Award

Prof. Dr. Dukagjin Blakaj | The Ohio State University | United States

Dr. Dukagjin M. Blakaj is a visionary leader in radiation oncology, currently serving as the Drs. Malati and Ganesh Potdar Endowed Professor and Vice Chair of Clinical Operations at The Ohio State University Comprehensive Cancer Center. Renowned for advancing proton therapy and translational cancer research, he has overseen exponential growth in departmental faculty, revenue, and NIH funding since joining in 2013. His leadership has transformed clinical operations, implemented strategic innovations, and significantly expanded clinical trial participation. Dr. Blakaj has mentored numerous faculty and fellows, initiated multi-disciplinary research collaborations, and secured millions in philanthropic and research funding. An influential educator and administrator, he also directs fellowships in Head & Neck, CNS/Pediatric, and IORT radiation oncology. Beyond his institutional impact, he serves on national committees and journal boards, shaping the future of cancer research and care. His work exemplifies excellence in clinical innovation, academic mentorship, and collaborative leadership across the oncology landscape.

Profile

Scopus
Orcid
Google Scholar

Education

Dr. Dukagjin Blakaj holds a distinguished academic background with dual advanced degrees in medicine and science. He earned his M.D. and Ph.D. in Biochemistry from the Albert Einstein College of Medicine, where he also completed a Master of Science in Biochemistry. Prior to that, he obtained both his Master of Arts and Bachelor of Arts degrees in Chemistry and Molecular Biology & Biophysics from Wesleyan University. His academic excellence is reflected in numerous accolades, including the Rudin Scholarship and Dean’s Recognition Award. He completed his internship in internal medicine at Mount Sinai Beth Israel Medical Center and a residency in radiation oncology at Montefiore-Einstein Comprehensive Cancer Center. Further, he undertook a post-doctoral fellowship focused on HPV epidemiology and therapeutic vaccine development. Dr. Blakaj’s academic training is complemented by multiple faculty leadership and coaching certifications, which have equipped him with the strategic and educational tools to excel as a clinical and academic leader in oncology.

Experience

With over a decade of experience at The Ohio State University Comprehensive Cancer Center, Dr. Dukagjin Blakaj has held progressive leadership roles, including Director of Head & Neck/Skull Base Division, Director of Clinical Operations, and currently Vice Chair of Clinical Operations. Under his guidance, the department expanded from 13 to 51 faculty members, increased revenue by over 450%, and tripled NIH funding. He has played a pivotal role in enhancing operational efficiencies, developing data lakes for research, and implementing standardized procedures across divisions. As a fellowship director in multiple subspecialties, he has trained future leaders in radiation oncology. His innovative leadership has advanced FLASH radiotherapy, Theranostics, and multidisciplinary care models. Dr. Blakaj also serves as Co-PI on several clinical trials and large-scale grants, leading to substantial contributions in patient care and translational research. His collaborative, data-driven approach continues to drive excellence in academic medicine and clinical cancer care.

Research Interests

Dr. Dukagjin Blakaj’s research spans translational oncology, radiation therapy innovations, and molecular mechanisms of treatment resistance. He focuses extensively on head and neck, skull base, and spine malignancies, leading efforts to develop precision radiation protocols and novel therapeutic strategies. His research has garnered over $5 million in funding, supporting groundbreaking clinical trials, including studies on FLASH radiotherapy, immunotherapy combinations, and stereotactic treatments. He is Principal or Co-Investigator on numerous NIH, industry-sponsored, and institutional grants addressing treatment optimization, radio-sensitization, and rare cancer biology. His work includes building large-scale clinical databases and integrating radiomic and molecular data into patient care models. He co-leads the PARTNER protocol to create a comprehensive data lake for translational research. His commitment to collaborative research has elevated institutional trial accruals and contributed to over 200 peer-reviewed publications. Through mentorship, innovation, and cross-disciplinary collaboration, Dr. Blakaj is advancing personalized oncologic care on both clinical and molecular fronts.

Awards and Honors

Dr. Dukagjin Blakaj has received numerous prestigious awards recognizing his contributions to oncology, research, and education. Notably, he received the James Outstanding Physician Peer Award for his leadership, professionalism, and collaborative spirit. He has consistently ranked among the top 10% of most published and cited doctors on Doximity (2021–2024) and was named a Top Doctor nationally in 2021. His article in Practical Radiation Oncology was selected for Elsevier’s Head & Neck Cancer Awareness Month feature. Additional accolades include the Best Teacher Award at the Osler Board Review Course, the Samuel J. Roessler Memorial Scholarship, and multiple abstract and travel awards from ASTRO, ACRO, and other leading organizations. He was also a finalist for the 2021 International Book Awards for his leadership publication. His early academic excellence was recognized through fellowships from the American Heart Association, Howard Hughes Medical Institute, and the International Biophysical Society, setting the foundation for his distinguished career.

 Publications Top Notes

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)

Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer

Time to surgery and survival in head and neck cancer

Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

NRG-HN002: a randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer

Single-isocenter multitarget stereotactic radiosurgery is safe and effective in the treatment of multiple brain metastases

Molecular dynamics and thermodynamics of protein−RNA interactions: Mutation of a conserved aromatic residue modifies stacking interactions and structural adaptation in the U1A protein

Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study

Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies

A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma

Evolutionary and biophysical relationships among the papillomavirus E2 proteins

Emerging concepts and novel strategies in radiation therapy for laryngeal cancer management

A digital twin for simulating the vertebroplasty procedure and its impact on mechanical stability of vertebra in cancer patients

Conclusion

Dr. Dukagjin M. Blakaj stands as a leading force in academic radiation oncology, seamlessly integrating clinical excellence, visionary leadership, and groundbreaking research. His transformative impact at The Ohio State University has resulted in institutional growth, enriched patient care, and elevated academic standards. A dedicated mentor and educator, he has cultivated the next generation of oncology leaders through innovative fellowships and global mentorship. His expansive research portfolio spans molecular biology, clinical trials, and AI-driven data analysis, reflecting a commitment to precision medicine and translational impact. Recognized nationally and internationally for his achievements, Dr. Blakaj continues to shape the future of radiation oncology through strategic leadership, collaborative partnerships, and compassionate care. His efforts exemplify how visionary thinking, paired with operational excellence, can revolutionize patient outcomes and institutional success. Dr. Blakaj remains a beacon of excellence in medicine, embodying the ideals of academic leadership, research innovation, and unwavering dedication to improving human health.

Nazia chaudhary | Cancer Biology | Best Researcher Award

Published on by Best Achievements

Dr. Nazia chaudhary | Cancer Biology | Best Researcher Award

Dr. Nazia chaudhary, ACTREC, TMC, India

Dr. Nazia S. Chaudhary is a DST Inspire Faculty at ACTREC-TMC, recognized for her groundbreaking work in cancer research. She earned her Ph.D. in 2022 from ACTREC (HBNI) and holds an M.Sc. from St. Xavier’s College, Mumbai. Her research focuses on tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities, with significant contributions to colorectal and breast cancer studies. Dr. Chaudhary has co-authored numerous high-impact publications and holds patents on therapeutic antibodies. She has presented her work at prestigious conferences globally and received accolades, including the DST Inspire Faculty Award and recognition for excellence in biological sciences.

Author Profile:

🎓 Education:

Dr. Nazia S. Chaudhary holds a Ph.D. in Cancer Biology from ACTREC (Homi Bhabha National Institute), which she completed in 2022. Her doctoral research explored critical aspects of tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities in cancer. Prior to her Ph.D., she earned her M.Sc. in Life Sciences from St. Xavier’s College, Mumbai, where she developed a strong foundation in molecular and cellular biology. Dr. Chaudhary’s academic journey has been marked by exceptional performance, laying the groundwork for her impactful research career. Her educational achievements reflect her dedication to advancing scientific knowledge in cancer biology and therapeutic innovation.

💼 Professional Experience:

Dr. Nazia S. Chaudhary is a DST Inspire Faculty at ACTREC-TMC, where she leads innovative research in cancer biology. She completed her Ph.D. in 2022 from ACTREC (HBNI), focusing on tumorigenesis and therapeutic resistance mechanisms. Dr. Chaudhary has extensive experience in identifying chemo-radio resistance pathways and exploring therapeutic vulnerabilities in colorectal and breast cancers. Her professional expertise spans molecular oncology, antibody development, and translational research, leading to impactful publications and patents. She has presented her findings at leading international conferences and collaborates with multidisciplinary teams to advance cancer therapeutics. Her work has earned her prestigious awards and recognition.

🌍Research Contributions:

Dr. Nazia S. Chaudhary has made significant contributions to cancer research, particularly in understanding tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities. Her work has advanced knowledge of colorectal and breast cancers, identifying novel molecular mechanisms that drive cancer progression and resistance to therapies. She has co-authored numerous high-impact publications in reputed journals, showcasing her innovative findings. Dr. Chaudhary’s research has led to patents on therapeutic antibodies, offering potential breakthroughs in targeted cancer treatments. Her contributions have been presented at renowned international conferences, reflecting her commitment to advancing cancer biology and developing effective therapeutic strategies for improved patient outcomes.

🥇Award and Honors:

Dr. Nazia S. Chaudhary has received numerous awards and honors for her outstanding contributions to cancer research. She was honored with the prestigious DST Inspire Faculty Award for her innovative work in tumor biology and therapeutic strategies. Her exceptional research has earned recognition at national and international platforms, including accolades for excellence in biological sciences. Dr. Chaudhary’s groundbreaking discoveries in chemo-radio resistance and therapeutic vulnerabilities have been acknowledged through awards at esteemed conferences and institutions. She also holds patents for therapeutic antibodies, reflecting her pioneering contributions to cancer therapeutics and her commitment to advancing translational research.

Conclusion:

Dr. Nazia S. Chaudhary’s exemplary contributions to cancer research have advanced our understanding of tumor biology, therapeutic resistance, and targeted interventions. Her innovative work on colorectal and breast cancer, coupled with her patents on therapeutic antibodies, highlights her dedication to developing effective treatment strategies. With a strong publication record and international recognition, Dr. Chaudhary continues to push the boundaries of cancer research, addressing critical challenges in oncology. Her achievements serve as a testament to her scientific excellence, making her a leading figure in the field and inspiring future advancements in cancer therapeutics and precision medicine.

📚Publication Top Notes:

Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer
International Journal of Cancer 149(7), 1495-1511, 135 citations, 2021 📈🧬

Plakophilin3 loss leads to an increase in lipocalin2 expression, which is required for tumour formation
Experimental Cell Research 369(2), 251-265, 25 citations, 2018 🔬🧪

Thermophilic actinomycetes from hot water spring capable of producing enzymes of industrial importance
Int J Res Stud Biosci 4, 29-35, 15 citations, 2016 🌿🌡️

Tumor-specific overexpression of histone gene, H3C14 in gastric cancer is mediated through EGFR-FOXC1 axis
Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1864(4-5), 2021, 14 citations 🔬🧬

Lipocalin 2 inhibits actin glutathionylation to promote invasion and migration
FEBS Letters 597(8), 1086-1097, 4 citations, 2023 ⚡🔬

Spatial Epidemiology of Signet-ring Cell Colorectal Cancer in India
Saudi Journal of Medicine & Medical Sciences 12(1), 71-75, 3 citations, 2024 🌍📊

Plakophilin3 loss leads to an increase in autophagy and radio-resistance
Biochemical and Biophysical Research Communications 620, 1-7, 3 citations, 2022 🔄📉

LCN2 and colon cancer—Have we hit the jackpot.
Journal of Clinical Oncology 38(15_suppl), e15608-e15608, 2 citations, 2020 🎯🔬

Elevated translationally controlled tumour protein promotes oral cancer progression and poor outcome
Journal of Oral Pathology & Medicine 52(9), 849-859, 1 citation, 2023 🦷🦠

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
bioRxiv, 2023.07.17.549374, 1 citation, 2023 🔬⚡

GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibition
bioRxiv, 2023.05.18.541287, 1 citation, 2023 🔬🔑